IDH1 and astrocytoma (excluding glioblastoma): As we better understand the granularity of IDH1/2-mutant astrocytoma molecular alterations from population-level analyses, it becomes critical to consider the composition of each tumor’s unique molecular signature when counseling and managing these patients.